Explore

Trendline Trendline
Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options

Dasher Neuroscience Completes Enrollment for AI-Driven MSA Drug Trial, Paving Way for New Treatment Options
Trendline Trendline
AI's Role in Drug Discovery: Potential and Challenges Highlighted

AI's Role in Drug Discovery: Potential and Challenges Highlighted

AI's Role in Drug Discovery: Potential and Challenges Highlighted
Trendline Trendline
Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets

Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets

Capricor Criticizes FDA's Use of 'Obsolete' Analysis in Deramiocel Review, Stock Plummets
Trendline Trendline
Dasher Neuroscience Completes Enrollment for Phase 2 Trial of AI Drug for MSA

Dasher Neuroscience Completes Enrollment for Phase 2 Trial of AI Drug for MSA

Dasher Neuroscience Completes Enrollment for Phase 2 Trial of AI Drug for MSA
Trendline Trendline
AstraZeneca Reports Strong H1 and Q2 2026 Financial Results Amidst Strategic Developments

AstraZeneca Reports Strong H1 and Q2 2026 Financial Results Amidst Strategic Developments

AstraZeneca Reports Strong H1 and Q2 2026 Financial Results Amidst Strategic Developments
Trendline Trendline
Incyte Reports Strong Q2 2026 Financial Results and Strategic Developments

Incyte Reports Strong Q2 2026 Financial Results and Strategic Developments

Incyte Reports Strong Q2 2026 Financial Results and Strategic Developments
Trendline Trendline
MapLight's Schizophrenia Drug Fails to Surpass Cobenfy in Phase 2 Trial, Leading to Stock Decline

MapLight's Schizophrenia Drug Fails to Surpass Cobenfy in Phase 2 Trial, Leading to Stock Decline

MapLight's Schizophrenia Drug Fails to Surpass Cobenfy in Phase 2 Trial, Leading to Stock Decline
Trendline Trendline
Arcturus Therapeutics to Announce Second Quarter Financial Results and Corporate Update

Arcturus Therapeutics to Announce Second Quarter Financial Results and Corporate Update

Arcturus Therapeutics to Announce Second Quarter Financial Results and Corporate Update
Trendline Trendline
Ascletis Reports Superior Weight Loss Results for ASC37 in Obese Mouse Model

Ascletis Reports Superior Weight Loss Results for ASC37 in Obese Mouse Model

Ascletis Reports Superior Weight Loss Results for ASC37 in Obese Mouse Model
Trendline Trendline
Dasher Neuroscience Completes Enrollment for Phase 2 Trial of YA-101 for MSA

Dasher Neuroscience Completes Enrollment for Phase 2 Trial of YA-101 for MSA

Dasher Neuroscience Completes Enrollment for Phase 2 Trial of YA-101 for MSA
Trendline Trendline
Gossamer Bio Reacquires Worldwide Rights to Seralutinib, Plans NDA Submission

Gossamer Bio Reacquires Worldwide Rights to Seralutinib, Plans NDA Submission

Gossamer Bio Reacquires Worldwide Rights to Seralutinib, Plans NDA Submission
Trendline Trendline
Tonix Pharmaceuticals to Announce Q2 2026 Financial Results Amid Expanding Treatment Portfolio

Tonix Pharmaceuticals to Announce Q2 2026 Financial Results Amid Expanding Treatment Portfolio

Tonix Pharmaceuticals to Announce Q2 2026 Financial Results Amid Expanding Treatment Portfolio